{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:43Z","timestamp":1774538683194,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,24]],"date-time":"2006-01-24T00:00:00Z","timestamp":1138060800000},"content-version":"vor","delay-in-days":815,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> The role of androgens in women's health has been generally neglected. Currently available assays are lacking in sensitivity and reliability at the lower ranges. Circulating androgens as prohormones for other steroids (e.g., androgens) have an ubiquitous role on diverse physiological and behavioral systems. Clinical assessment of both androgen production and androgen availability can be achieved by measurement of two or three essential values. These include either total T and sex\u2010hormone binding globulin (SHBG), free T and SHBG, or free T and total T. The free testosterone index (total T\/SHBG) correlates well with free or bioavailable T and can be used as a substitute. DHEA\u2010S is the most useful measure of adrenal androgen production in women. Androgen insufficiency in women is not a specific consequence of natural menopause, but may occur secondarily to the age\u2010related decline in both adrenal and ovarian androgen production. Since estrogen effects are also strongly linked to mood, psychological well\u2010being, and sexual function in women, the diagnosis of androgen insufficiency should only be made in women who are adequately estrogenized. Before initiating a trial of androgen replacement therapy, a comprehensive clinical assessment should be performed in all cases. Approved androgen replacement therapy is not yet available in most countries for treatment of female sexual dysfunction. This would include T supplements or DHEA. Several new progestins have been synthesized in the last decade. Dienogest is a hybrid progestin that is derived from both the pregnane and the estrane groups with a 17\u03b1\u2010cyanomethyl radical; drospirenone is derived from spirolactone. Somehow, the molecules available have demonstrated antiandrogenic properties. Cyproterone acetate (CPA) is the most potent antiandrogenic progestin, followed by dienogest, drosperinone, and chlormadinone acetate. Nomegestrol acetate and medrogestone also exert some antiandrogenic properties and are similar to chlormadinone acetate in antiandrogenic potency. While androgens act positively on libido in women, antiandrogenic properties in doses used in HRT do not appear to have a negative effect. Progestins used in HRT have varying pharmacological properties that are associated with different adverse effects. The new progestins with antiandrogenic properties avoid many of the androgenic side effects related to testosterone\u2010derived progestins. They also have the potential of not counteracting beneficial estrogen effects, for example, on the cardiovascular system or mental tone.<\/jats:p>","DOI":"10.1196\/annals.1290.033","type":"journal-article","created":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T01:04:15Z","timestamp":1074128655000},"page":"292-306","source":"Crossref","is-referenced-by-count":41,"title":["Androgens and Antiandrogens"],"prefix":"10.1111","volume":"997","author":[{"given":"H. P. G.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/57.2.M76"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90057-3"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.2.7219"},{"key":"e_1_2_5_5_2","first-page":"609","article-title":"Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle\u2010aged men","volume":"146","author":"Zmuda J.M.","year":"1997","journal-title":"A 13-year follow-up of former Multiple Risk Factor Intervention Trial Participants. Am. J. Epidemiol."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)02969-2"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05599-R"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704303161801"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.1991.03460050081025","article-title":"Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? J","volume":"265","author":"Barrett\u2010Connor E.","year":"1991","journal-title":"Am. Med. Assoc."},{"key":"e_1_2_5_10_2","first-page":"605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley S.","year":"1998","journal-title":"Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008243430801"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_5_13_2","first-page":"2825","article-title":"Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR\u20101) expression","volume":"104","author":"Herkert O.","year":"2001","journal-title":"Role of the glucocorticoid receptor. Circulation"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70045-1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00144-9"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200101000-00008"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92555-8"},{"key":"e_1_2_5_18_2","first-page":"14","article-title":"Sex steroids, bone mass and bone loss","volume":"97","author":"Selemenda C.","year":"1996","journal-title":"A prospective study of pre-, peri- and postmenopausal women. J. Clin. Invest."},{"key":"e_1_2_5_19_2","first-page":"1012","article-title":"A two\u2010year, double\u2010blind comparison of estrogen\u2010androgen and conjugated estrogens in surgically menopausal women","volume":"44","author":"Barrett\u2010Connor E.","year":"1999","journal-title":"Effects on bone mineral density, symptoms and lipid profiles. J. Reprod. Med."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(94)00898-H"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-4-651"},{"key":"e_1_2_5_22_2","first-page":"275","article-title":"Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures","volume":"61","author":"Davidson B.J.","year":"1983","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002230010084"},{"issue":"1","key":"e_1_2_5_24_2","first-page":"73","article-title":"Androgen levels in normal and oophorectomized women","volume":"5","author":"Davis S.R.","year":"2002","journal-title":"Climacteric"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.3.427"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5357.1631"},{"key":"e_1_2_5_27_2","unstructured":"Bondy C.A. & C. Dimitrakakis. 2002. Androgens and breast cancer risk.InMenopause: The State of the Art\u2014In Research and Management. The Proceedings of the 10thWorld Congress on the Menopause. H.P.G. Schneider Ed.: 28\u201335. Parthenon. London."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(95)00005-K"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-1-392"},{"key":"e_1_2_5_30_2","unstructured":"Dimitrakakis C. J. Zhou & C.A. Bondy. 2002. A physiologic role for testosterone in limiting primate mammary epithelial proliferation in vivo. 93rdAnnu. Meet. American Association for Cancer Research: 505. San Francisco CA."},{"key":"e_1_2_5_31_2","unstructured":"Henzl M.R. & J.A. Edwards. 2000. Pharmacology of progestins: 17\u03b1\u2010hydroxyprogesterone derivatives and progestins of the first and second generation.InProgestins and Antiprogestins in Clinical Practice. R. Sitruk\u2010Ware and D. Mishell Eds.: 101\u2013132. Dekker. New York."},{"key":"e_1_2_5_32_2","first-page":"3","article-title":"Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy","volume":"37","author":"Oettel M.","year":"2001","journal-title":"Drugs Today"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00133-5"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.6.1816"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200201000-00003"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(98)00085-1"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(84)90164-1"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-2-304"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6454.1257"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(90)90096-2"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.2.3735"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/13697130009167612"},{"key":"e_1_2_5_43_2","first-page":"115","article-title":"Dienogest as a progestin for hormone replacement therapy","volume":"35","author":"Graeser T.","year":"1999","journal-title":"Drugs Today"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(01)00169-4"},{"key":"e_1_2_5_45_2","first-page":"165","article-title":"Hormone replacement therapy and vigilance","volume":"43","author":"Saletu B.","year":"2002","journal-title":"Double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien\u00ae, Lafamme\u00ae) versus estrogen alone in menopausal syndrome patients. Maturitas."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1290.033","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1290.033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:38:56Z","timestamp":1695638336000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1290.033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1196\/annals.1290.033"],"URL":"https:\/\/doi.org\/10.1196\/annals.1290.033","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}